Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Abiraterone
Drug ID BADD_D00014
Description Abiraterone is a derivative of steroidal progesterone and is an innovative drug that offers clinical benefit to patients with hormone refractory prostate cancer. Abiraterone is administered as an acetate salt prodrug because it has a higher bioavailability and less susceptible to hydrolysis than abiraterone itself. FDA approved on April 28, 2011.
Indications and Usage Used in combination with prednisone for the treatment of metastatic, castration-resistant prostate cancer.
Marketing Status Not Available
ATC Code Not Available
DrugBank ID DB05812
KEGG ID Not Available
MeSH ID C089740
PubChem ID 132971
TTD Drug ID D02STN
NDC Product Code 17337-0082; 30007-838; 42291-073; 60687-455; 69238-1165; 42291-024; 69238-1754; 54893-0070
Synonyms abiraterone | 17-(3-pyridyl)androsta-5,16-dien-3beta-ol | CB-7598 | CB 7598 | CB7598
Chemical Information
Molecular Formula C24H31NO
CAS Registry Number 154229-19-3
SMILES CC12CCC(CC1=CCC3C2CCC4(C3CC=C4C5=CN=CC=C5)C)O
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Aortic stenosis24.04.01.0010.001471%Not Available
Aortic valve incompetence02.07.03.0010.001471%Not Available
Aphasia19.21.01.001; 17.02.03.001--
Aplastic anaemia01.03.03.0020.000384%Not Available
Appendicitis07.19.01.001; 11.01.07.0010.002942%
Arrhythmia02.03.02.0010.015445%Not Available
Arrhythmia supraventricular02.03.03.0010.002206%Not Available
Arthralgia15.01.02.001--
Arthritis15.01.01.001--
Ascites07.07.01.001; 02.05.04.002; 09.01.05.003--
Aspartate aminotransferase increased13.03.01.0060.016181%
Asphyxia22.02.02.001; 12.01.08.0110.000384%Not Available
Aspiration22.02.07.007--
Asthenia08.01.01.0010.093407%Not Available
Asthma22.03.01.002; 10.01.03.010--Not Available
Atrial fibrillation02.03.03.0020.027213%
Atrial flutter02.03.03.003--
Back disorder15.03.01.014--Not Available
Back pain15.03.04.005--
Basal cell carcinoma23.08.02.001; 16.03.02.001--Not Available
Bladder cancer16.08.01.001; 20.03.04.001--Not Available
Blindness unilateral17.17.01.016; 06.02.02.0090.002206%Not Available
Blister23.03.01.001; 12.01.06.0020.009561%Not Available
Blood albumin increased13.09.01.0020.004413%Not Available
Blood bilirubin increased13.03.01.008--
Blood calcium increased13.11.01.0030.002942%Not Available
Blood cholesterol increased13.12.01.002--
Blood creatine phosphokinase increased13.04.01.001--
Blood creatinine increased13.13.01.004--
Blood glucose decreased13.02.02.0010.004413%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 22 Pages